Quarterly Report (10-q)

0001620749false--07-312022-01-31Q2202239210000500000000.000100005500000000.000139210000392100003921000000016207492021-08-012022-01-3100016207492021-10-210001620749us-gaap:RetainedEarningsMember2022-01-310001620749us-gaap:AdditionalPaidInCapitalMember2022-01-310001620749pnht:CommonStocksMember2022-01-310001620749us-gaap:RetainedEarningsMember2021-11-012022-01-310001620749us-gaap:AdditionalPaidInCapitalMember2021-11-012022-01-310001620749pnht:CommonStocksMember2021-11-012022-01-3100016207492021-10-310001620749us-gaap:RetainedEarningsMember2021-10-310001620749us-gaap:AdditionalPaidInCapitalMember2021-10-310001620749pnht:CommonStocksMember2021-10-3100016207492021-08-012021-10-310001620749us-gaap:RetainedEarningsMember2021-08-012021-10-310001620749us-gaap:AdditionalPaidInCapitalMember2021-08-012021-10-310001620749pnht:CommonStocksMember2021-08-012021-10-310001620749us-gaap:RetainedEarningsMember2021-07-310001620749us-gaap:AdditionalPaidInCapitalMember2021-07-310001620749pnht:CommonStocksMember2021-07-3100016207492021-01-310001620749us-gaap:RetainedEarningsMember2021-01-310001620749us-gaap:AdditionalPaidInCapitalMember2021-01-310001620749pnht:CommonStocksMember2021-01-310001620749us-gaap:RetainedEarningsMember2020-11-012021-01-310001620749us-gaap:AdditionalPaidInCapitalMember2020-11-012021-01-310001620749pnht:CommonStocksMember2020-11-012021-01-3100016207492020-10-310001620749us-gaap:RetainedEarningsMember2020-10-310001620749us-gaap:AdditionalPaidInCapitalMember2020-10-310001620749pnht:CommonStocksMember2020-10-3100016207492020-08-012020-10-310001620749us-gaap:RetainedEarningsMember2020-08-012020-10-310001620749us-gaap:AdditionalPaidInCapitalMember2020-08-012020-10-310001620749pnht:CommonStocksMember2020-08-012020-10-3100016207492020-07-310001620749us-gaap:RetainedEarningsMember2020-07-310001620749us-gaap:AdditionalPaidInCapitalMember2020-07-310001620749pnht:CommonStocksMember2020-07-3100016207492020-08-012021-01-3100016207492020-11-012021-01-3100016207492021-11-012022-01-3100016207492021-07-3100016207492022-01-3100016207492022-03-17iso4217:USDxbrli:sharesiso4217:USDxbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 10-Q

(Mark One)

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

	For the quarterly period ended January 31, 2022

or

☐	TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

	For the transition period from ______________ to ______________

	Commission File Number 000-55569

PANAMERA HOLDINGS CORPORATION

(Exact name of registrant as specified in its charter)

Nevada		46-5707326
(State or other jurisdiction of incorporation or organization)		(IRS Employer Identification No.)

1218 Webster Street Houston, Texas		77002
(Address of principal executive offices)		(Zip Code)

(713) 289-6200

(Registrant’s telephone number, including area code)

Panamera Healthcare Corporation

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
None	None	None

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☒ Yes ☐ No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). ☒ Yes ☐ No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒
		Emerging growth company	☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act) ☒ Yes ☐ NO

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date. 39,210,000 shares of common stock issued and outstanding as of March 17, 2022

TABLE OF CONTENTS

PART I - FINANCIAL INFORMATION
Item 1.	Financial Statements	3
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	9
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	13
Item 4.	Controls and Procedures	13

PART II - OTHER INFORMATION
Item 1.	Legal Proceedings	14
Item 1A.	Risk Factors	14
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	14
Item 3.	Defaults Upon Senior Securities	14
Item 4.	Mine Safety Disclosures	14
Item 5.	Other Information	14
Item 6.	Exhibits	15
SIGNATURES		16

Table of Contents

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements

PANAMERA HOLDINGS CORPORATION

Balance Sheets

(Unaudited)

	January 31,			July 31,
	2022			2021
Assets
Current Assets
Cash	$	14		$	10
Total Current Assets		14			10

Total Assets	$	14		$	10

Liabilities and Stockholders' Deficit
Current Liabilities
Accounts payable	$	15,147		$	13,514
Due to related party		8,836			1,608
Total Current Liabilities		23,983			15,122

Total Liabilities		23,983			15,122

Stockholders' Deficit
Preferred stock: 50,000,000 authorized; $0.0001 par value, no shares issued and outstanding		-			-
Common stock: 550,000,000 authorized; $0.0001 par value, 39,210,000 shares issued and outstanding		3,921			3,921
Additional paid in capital		345,239			344,963
Accumulated deficit		(373,129	)		(363,996	)
Total Stockholders' Deficit		(23,969	)		(15,112	)
Total Liabilities and Stockholders' Deficit	$	14		$	10

The accompanying notes to the unaudited financial statements are an integral part of these statements.

Table of Contents

PANAMERA HOLDINGS CORPORATION

Statements of Operations

(Unaudited)

	For the						For the
	Three Months Ended						Six Months Ended
	January 31,						January 31,
	2022			2021			2022			2021

Operating expenses
Professional fees	$	5,305		$	4,332		$	5,333		$	14,835
General and administration expenses		932			352			3,344			585
Total operating expenses		6,237			4,684			8,677			15,420

Net loss from operations		(6,237	)		(4,684	)		(8,677	)		(15,420	)

Other Expense
Interest expense		(389	)		(1,457	)		(456	)		(2,853	)
Total other expense		(389	)		(1,457	)		(456	)		(2,853	)

Net loss before taxes		(6,626	)		(6,141	)		(9,133	)		(18,273	)

Income tax benefit		-			-			-			-

Net loss	$	(6,626	)	$	(6,141	)	$	(9,133	)	$	(18,273	)

Basic and diluted loss per common share	$	(0.00	)	$	(0.00	)	$	(0.00	)	$	(0.00	)

Weighted average number of common shares outstanding, basic and diluted		39,210,000			17,990,000			39,210,000			17,990,000

The accompanying notes to the unaudited financial statements are an integral part of these statements.

Table of Contents

PANAMERA HOLDINGS CORPORATION

Statements of Changes in Stockholders’ Deficit

(Unaudited)

For the Three and Six Months Ended January 31, 2022

					Additional
	Common Stock				Paid in		Accumulated
	Shares		Amount		Capital		Deficit			Total
Balance - July 31, 2021		39,210,000	$	3,921	$	344,963	$	(363,996	)	$	(15,112	)

Impact interest on related party loan		-		-		67		-			67
Net loss for the period		-		-		-		(2,507	)		(2,507	)
Balance - October 31, 2021		39,210,000		3,921		345,030		(366,503	)		(17,552	)

Impact interest on related party loan		-		-		209		-			209
Net loss for the period		-		-		-		(6,626	)		(6,626	)
Balance - January 31, 2022		39,210,000	$	3,921	$	345,239	$	(373,129	)	$	(23,969	)

For the Three and Six Months Ended January 31, 2021

					Additional
	Common Stock				Paid in		Accumulated
	Shares		Amount		Capital		Deficit			Total
Balance - July 31 2020		17,990,000	$	1,799	$	145,750	$	(268,644	)	$	(121,095	)

Net loss for the period		-		-		-		(12,132	)		(12,132	)
Balance - October 31 2020		17,990,000		1,799		145,750		(280,776	)		(133,227	)

Net loss for the period		-		-		-		(6,141	)		(6,141	)
Balance - January 31, 2021		17,990,000	$	1,799	$	145,750	$	(286,917	)	$	(139,368	)

The accompanying notes to the unaudited financial statements are an integral part of these statements.

Table of Contents

PANAMERA HOLDINGS CORPORATION

Statements of Cash Flows

(Unaudited)

	For the
	Six Months Ended
	January 31,
	2022			2021

Cash Flows from Operating Activities:
Net loss	$	(9,133	)	$	(18,273	)
Adjustments to reconcile net loss to net cash used in operating activities:
Impact interest on related party loan		276			-
Changes in operating assets and liabilities:
Accounts payable		1,633			2,886
Accrued interest - related party		-			2,853
Net Cash Used in Operating Activities		(7,224	)		(12,534	)

Cash Flows from Financing Activities:
Proceeds from related party loans		7,228			10,450
Net Cash Provided by Financing Activities		7,228			10,450

Net change in cash		4			(2,084	)
Cash, beginning of period		10			2,232
Cash, end of period	$	14		$	148

Supplemental cash flow information:
Cash paid for interest	$	-		$	-
Cash paid for taxes	$	-		$	-

The accompanying notes to the unaudited financial statements are an integral part of these statements.

Table of Contents

PANAMERA HOLDINGS CORPORATION

Notes to the Unaudited Interim Financial Statements

January 31, 2022

NOTE 1 – ORGANIZATION, DESCRIPTION OF BUSINESS

Panamera Holdings Corporation (the “Company”) is a Nevada corporation incorporated on May 20, 2014. Effective October 21, 2021, the Company changed its name from Panamera Healthcare Corporation to Panamera Holdings Corporation and increased the number of authorized common stock from 150,000,000 shares of common stock to 550,000,000 shares of common stock, par value $0.0001 per share. The Company’s fiscal year end is July 31.

The Company originally intended to offer management and consulting services to healthcare organizations but current management have redirected efforts now to pursuing business opportunities including but not limited to the environmental services industry, emerging innovative technologies and individual health choices led by innovation with integration. To date, the Company’s activities have been limited to its formation and the raising of equity capital.

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The accompanying unaudited interim financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America for interim financial information and with the instructions to Form 10-Q and Regulation S-X. Accordingly, the unaudited interim financial statements do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements.

In the opinion of management, all adjustments consisting of normal recurring entries necessary for a fair statement of the periods presented for: (a) the financial position; (b) the result of operations; and (c) cash flows, have been made in order to make the unaudited interim financial statements presented not misleading. The results of operations for such interim periods are not necessarily indicative of operations for a full year. The accompanying unaudited interim financial statements should be read in conjunction with the financial statements and related notes included in the Company’s Annual Report on Form 10-K, for the year ended July 31, 2021, as filed with the SEC on February 15, 2022.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements. The estimates and judgments will also affect the reported amounts for certain expenses during the reporting period. Actual results could differ from these good faith estimates and judgments.

A novel strain of coronavirus (COVID-19) was first identified in December 2019, and subsequently declared a global pandemic by the World Health Organization on March 11, 2020. As a result of the outbreak, many companies have experienced disruptions in their operations and in markets served. The Company considered the impact of COVID-19 on the assumptions and estimates used and determined that there were no material adverse impacts on the Company’s results of operations and financial position at January 31, 2022. The full extent of the future impacts of COVID-19 on the Company’s operations is uncertain. A prolonged outbreak could have a material adverse impact on the Company’s ability to identify and/or consummate an acceptable merger or acquisition transaction.

Financial Instruments and Fair Value Measurements

The Company follows ASC 820, “Fair Value Measurements and Disclosures,” which defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.

Table of Contents

Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of January 31, 2022 and July 31, 2021. The carrying values of our financial instruments, including, cash, accounts payable and accrued expenses; and loans and notes payable approximate their fair values due to the short-term maturities of these financial instruments.

Commitments and Contingencies

The Company follows ASC 450-20, “Loss Contingencies,” to report accounting for contingencies. Liabilities for loss contingencies arising from claims, assessments, litigation, fines and penalties and other sources are recorded when it is probable that a liability has been incurred and the amount of the assessment can be reasonably estimated.

NOTE 3 - GOING CONCERN

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the liquidation of liabilities in the normal course of business. As of January 31, 2022, the Company has a loss from operations, an accumulated deficit and has not earned any revenues. The Company intends to fund operations through debt and/or equity financing arrangements and related party advances, which may be insufficient to fund its capital expenditures, working capital and other cash requirements for the year ending July 31, 2022.

The ability of the Company to emerge from an early stage is dependent upon, among other things, obtaining additional financing to continue operations, and development of its business plan. In response to these problems, management intends to raise additional funds through public or private placement offerings and/or engaging in a business combination.

These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying financial statements do not include any adjustments that might result from the outcome of this uncertainty.

NOTE 4 - RELATED PARTY TRANSACTIONS

During the year six months ended January 31, 2022, the Company’s shareholders financed of $7,228 for operation expenses. As of January 31, 2022, the Company was obliged for an unsecured, non-interest bearing demand loan with balance of $8,836. The Company recognized interest of $276 on advance by related party and recorded it as additional paid-in-capital.

The Company does not own or lease property or lease office space. The office space used by the Company was arranged by the founder, who is also a director of the Company, to use at no charge.

NOTE 5 - STOCKHOLDERS’ EQUITY

Preferred Stock

The Company has authorized 50,000,000 shares of preferred stock with a par value of $0.0001 per share. No preferred stock was issued or outstanding as at January 31, 2022 and July 31, 2021.

Common Stock

The Company has authorized 550,000,000 shares of common stock with a par value of $0.0001 per share.

As of January 31,2022 and July 31, 2021, there were 39,210,000 shares of common stock issued and outstanding, respectively.

NOTE 6 – SUBSEQUENT EVENTS

Management has evaluated subsequent events through the date these financial statements were available to be issued. Based on our evaluation no material events have occurred that require disclosure.

Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

FORWARD-LOOKING STATEMENTS

This quarterly report contains forward-looking statements. These statements relate to future events or our future financial performance. In some cases, you can identify forward-looking statements by terminology such as “may”, “should”, “expects”, “plans”, “anticipates”, “believes”, “estimates”, “predicts”, “potential” or “continue” or the negative of these terms or other comparable terminology. These statements are only predictions and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to actual results.

Our unaudited financial statements are prepared in accordance with United States Generally Accepted Accounting Principles. The following discussion should be read in conjunction with our financial statements and the related notes that appear elsewhere in this quarterly report. The following discussion contains forward-looking statements that reflect our plans, estimates and beliefs. Our actual results could differ materially from those discussed in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed below and elsewhere in this quarterly report.

In this quarterly report, unless otherwise specified, all dollar amounts are expressed in United States dollars and all references to “common shares” refer to the common shares in our capital stock.

As used in this quarterly report, the terms “we”, “us”, “our” and “our Company” mean Panamera Holdings Corporation, unless otherwise indicated.

General Overview

We were incorporated under the laws of the State of Nevada on May 20, 2014. Effective October 21,2021, the Company changed its name from Panamera Healthcare Corporation to Panamera Holdings Corporation and increased the number of authorized common stock from 150,000,000 shares of common stock to 550,000,000 shares of common stock, par value $0.0001per share. Prior management intended to offer management and consulting services to healthcare organizations, but current management have redirected our efforts now to pursuing business opportunities including but not limited to the environmental services industry, emerging innovative technologies and individual health choices led by innovation with integration.

We have since changed our focus to looking for other business opportunities to implement and/or operating companies with which to engage in a business combination as described above.

Our address is 1218 Webster Street, Houston, Texas. Our telephone number is (713) 289-6200.

We have not ever declared bankruptcy, been in receivership, or involved in any kind of legal proceeding.

The following discussion should be read in conjunction with our financial statements, including the notes thereto, appearing elsewhere in this annual report. The following discussion contains forward-looking statements that reflect our plans, estimates and beliefs. Our actual results could differ materially from those discussed in the forward-looking statements. Factors that could cause or contribute to such differences include but are not limited to those discussed below and elsewhere in this report. Our unaudited financial statements are stated in United States Dollars and are prepared in accordance with United States Generally Accepted Accounting Principles.

Table of Contents

COVID-19

A novel strain of coronavirus (COVID-19) was first identified in December 2019, and subsequently declared a global pandemic by the World Health Organization on March 11, 2020. As a result of the outbreak, many companies have experienced disruptions in their operations and in markets served. The Company considered the impact of COVID-19 on the assumptions and estimates used and determined that there were no material adverse impacts on the Company’s results of operations and financial position as of January 31, 2022. The full extent of the future impacts of COVID-19 on the Company’s plan of operations is uncertain. A prolonged outbreak could have a material adverse impact on the Company’s ability to identify and implement new business opportunities and/or consummate an acceptable merger or acquisition transaction.

Plan of Operations and Cash Requirements

We are no longer attempting to implement our original business plan. We now intend to look for other business opportunities to implement and/or operating companies with which to engage in a business combination including but not limited to the environmental services industry, emerging innovative technologies and individual health choices led by innovation with integration. Our focus will be on achieving long-term growth potential.

The analysis of new business opportunities will be undertaken by or under the supervision of the Company’s management. While the Company has limited assets and no operating revenues, the Company has unrestricted flexibility in seeking, analyzing and participating in potential business opportunities and/or combinations in in any type of business, industry or geographical location. In its efforts, the Company will consider the following kinds of factors:

(a) potential for growth, indicated by new technology, anticipated market expansion or new products.

(b) competitive position as compared to other operations of similar size and experience within the industry segment as well as within the industry as a whole.

(d) capital requirements and anticipated availability of required funds, to be provided by the Company or from operations, through the sale of additional securities, through joint ventures or similar arrangements or from other sources.

(e) the cost of participation by the Company as compared to the perceived tangible and intangible values and potentials.

(f) the extent to which the business opportunity can be advanced; and

(g) the accessibility of required management expertise, personnel, raw materials, services, professional assistance and other required items.

In applying the foregoing criteria, not one of which will be controlling, management will attempt to analyze all factors and circumstances and make a determination based upon reasonable investigative measures and available data. Potentially available opportunities may occur in many different industries, and at various stages of development, all of which will make the task of comparative investigation and analysis of such business opportunities extremely difficult and complex. Due to the Registrant’s limited capital available for investigation, the Registrant may not discover or adequately evaluate adverse facts about the opportunity to be acquired. In addition, we will be competing against other entities that possess greater financial, technical and managerial capabilities for identifying and completing the implementation of any opportunities and/or business combinations.

Table of Contents

Results of Operations

The following summary of our results of operations should be read in conjunction with our unaudited financial statements for the period ended January 31, 2022, which are included herein.

Our operating results for the six months ended January 31, 2022 and 2021 and the changes between those periods for the respective items are summarized as follows.

Results of Operations for the three months ended January 31,2022 and 2021

	Three Months Ended
	January 31,
	2022		2021		Changes
Operating expenses	$	6,237	$	4,684	$	1,553
Interest expense	$	389	$	1,457	$	(1,068	)
Net loss	$	6,626	$	6,141	$	485

During the three months ended January 31, 2022 and 2021, no revenues were recorded.

We had a net loss of $6,626 for the three months ended January 31, 2022, and $6,141 for the three months ended January 31, 2021. The increase in net loss of $485, was due to an increase in operating expenses of $1,553 offset by a decrease in interest expenses of $1,068.

Operating expenses for the three months ended January 31, 2022 and 2021 were $6,237 and $4,684, respectively. For the three months ended January 31, 2022, the operating expenses were primarily attributed to professional fees for maintaining reporting status with the Securities and Exchange Commission (“SEC”) of $5,305 and general and administrative expenses of $932. For the three months ended January 31,2021, the operating expenses were primarily attributed to professional fees for maintaining reporting status with the Securities and Exchange Commission (“SEC”) of $4,332 and general and administrative expenses of $352.

Interest expenses for the three months ended January 31, 2022 and 2021, represent interest expense of $209 and $1,457 to a related party on funds advanced to the Company and finance charged of $180 and $0 by vendors, respectively.

Results of Operations for the six months ended January 31,2022 and 2021

	Six Months Ended
	January 31,
	2022		2021		Changes
Operating expenses	$	8,677	$	15,420	$	(6,743	)
Interest expense	$	456	$	2,853	$	(2,397	)
Net loss	$	9,133	$	18,273	$	(9,140	)

During the six months ended January 31, 2022 and 2021, no revenues were recorded.

We had a net loss of $9,133 for the six months ended January 31,2022, and $18,273 for the six months ended January 31, 2021. The decrease in net loss of $9,140, was due to a decrease in operating expenses of $6,743 and interest expenses of $2,397.

Operating expenses for the six months ended January 31, 2022 and 2021 were $8,677 and $15,420, respectively. For the six months ended January 31, 2022, the operating expenses were primarily attributed to professional fees for maintaining reporting status with the Securities and Exchange Commission (“SEC”) of $5,333 and general and administrative expenses of $3,344. For the six months ended January 31,2021, the operating expenses were primarily attributed to professional fees for maintaining reporting status with the Securities and Exchange Commission (“SEC”) of $14,835 and general and administrative expenses of $585.

Interest expenses for the six months ended January 31, 2022 and 2021, represent interest expense of $276 and $2,853 to a related party on funds advanced to the Company and finance charged of $180 and $0 by vendors, respectively.

Table of Contents

Balance Sheet Data:

	January 31, 2022			July 31, 2021			Changes
Cash	$	14		$	10		$	4
Working capital deficiency	$	(23,969	)	$	(15,112	)	$	(8,857	)
Total assets	$	14		$	10		$	4
Total liabilities	$	23,983		$	15,122		$	8,861
Total stockholders' deficit	$	(23,969	)	$	(15,112	)	$	(8,857	)

As of January 31, 2022, our current assets were $14, and our current liabilities were $23,983 which resulted in working capital deficiency of $23,969. As of January 31, 2022, current assets were comprised of $14 in cash, compared to $10 in cash as of July 31, 2021. As of January 31, 2022, current liabilities were comprised of $15,147 in accounts payable and $8,836 in due to related party, compared to $13,514 in accounts payable and $1,608 in due to related party as of July 31, 2021.

As of January 31, 2022, our working capital deficiency increased by $8,857 from $15,112 on July 31, 2021, to $23,969 on January 31, 2022, primarily due to an increase in current liabilities of $8,861 and offset by an increase in current assets of $4.

Cash Flow Data:

	Six Months Ended
	January 31,
	2022			2021			Changes
Cash Flows used in Operating Activities	$	(7,224	)	$	(12,534	)	$	5,310
Cash Flows used in Investing Activities	$	-		$	-		$	-
Cash Flows provided by Financing Activities	$	7,228		$	10,450		$	(3,222	)
Net Change in Cash During Period	$	4		$	(2,084	)	$	2,088

Cash Flows from Operating Activities

We have not generated positive cash flows from operating activities. For the six months ended January 31, 2022, net cash flows used in operating activities was $7,224, consisting of a net loss of $9,133, reduced by imputed interest on related party loan of $276 and reduced by an increase in accounts payable of $1,633. For the six months ended January 31, 2021, net cash flows used in operating activities was $12,534, consisting of a net loss of $18,273, reduced by an increase in accrued interest -related party of $2,853 and an increase in accounts payable of $2,886.

Cash Flows from Financing Activities

We have financed our operations loans from a related party. For the six months ended January 31, 2022, and 2021, we received $7,228 and $10,450 from advances to pay certain operation expenses from related party loans, respectively.

Going Concern

As of January 31, 2022, our company had a net loss of $9,133 and has earned no revenues. Our company intends to fund operations through equity financing arrangements, which may be insufficient to fund its capital expenditures, working capital and other cash requirements for the year ending July 31, 2022. The ability of our company to emerge from the development stage is dependent upon, among other things, obtaining additional financing to continue operations, and development of our business plan. In response to these problems, management intends to raise additional funds through public or private placement offerings. These factors, among others, raise substantial doubt about our company’s ability to continue as a going concern. The accompanying financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Critical Accounting Policies

The discussion and analysis of our financial condition and results of operations are based upon our financial statements, which have been prepared in accordance with the accounting principles generally accepted in the United States of America. Preparing financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, and expenses. These estimates and assumptions are affected by management’s application of accounting policies. We believe there are no material estimates or assumptions with levels of subjectivity and judgement necessary to be considered critical accounting policies.

Off-Balance Sheet Arrangements

We have no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to stockholders.

Table of Contents

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

As a “smaller reporting company,” we are not required to provide the information required by this Item.

Item 4. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

Our management is responsible for establishing and maintaining a system of disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) under the Exchange Act) that is designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Commission’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by an issuer in the reports that it files or submits under the Exchange Act is accumulated and communicated to the issuer’s management, including its principal executive officer or officers and principal financial officer or officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

An evaluation was conducted under the supervision and with the participation of our management of the effectiveness of the design and operation of our disclosure controls and procedures as of October 31, 2021. Based on that evaluation, our management concluded that our disclosure controls and procedures were not effective as of such date to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act, is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms as a result of the following material weaknesses: (1) lack of a functioning audit committee, (2) lack of a majority of outside directors on our Board of Directors, resulting in ineffective oversight in the establishment and monitoring of required internal controls and procedures; (3) inadequate segregation of duties consistent with control objectives; and (4) management is dominated by two individuals without adequate compensating controls.

A “material weakness” is a deficiency, or combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of the Company’s annual or interim financial statements would not be prevented or detected on a timely basis.

We expect to be materially dependent upon a third party to provide us with accounting consulting services for the foreseeable future. Until such time as we have a chief financial officer with the requisite expertise in U.S. GAAP, there are no assurances that the material weaknesses in our disclosure controls and procedures and internal control over financial reporting will not result in errors in our financial statements which could lead to a restatement of those financial statements.

Changes in Internal Controls

There have been no changes in our internal controls over financial reporting identified in connection with the evaluation required by paragraph (d) of Securities Exchange Act Rule 13a-15 or Rule 15d-15 that occurred in the three months ended October 31, 2021, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Table of Contents

PART II - OTHER INFORMATION

Item 1. Legal Proceedings.

From time to time, we may become involved in litigation relating to claims arising out of our operations in the normal course of business. We are not involved in any pending legal proceeding or litigation, and, to the best of our knowledge, no governmental authority is contemplating any proceeding to which we are a party, and which would reasonably be likely to have a material adverse effect on our Company. To date, our Company has never been involved in litigation, as either a party or a witness, nor has our Company been involved in any legal proceedings commenced by any regulatory agency against our Company.

Item 1A. Risk Factors.

As a “smaller reporting company,” we are not required to provide the information required by this Item.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

None.

Item 3. Defaults Upon Senior Securities.

None.

Item 4. Mine Safety Disclosures.

Not Applicable.

Item 5. Other Information.

None.

Table of Contents

Item 6. Exhibits.

The following exhibits are included as part of this report:

Exhibit Number		Description
(3)		Articles of Incorporation and Bylaws
3.1		Articles of Incorporation (Incorporated by reference to our Registration Statement on Form S-1 filed on September 26, 2014)
3.2		Bylaws (Incorporated by reference to our Registration Statement on Form S-1 filed on September 26, 2014)
(14)		Code of Ethics
14.1		Code of Ethics for Directors, Officers, and Employees (incorporated by reference to exhibit 14.1 in our Registration Statement on Form S-1 filed on September 26, 2014)
14.2		Code of Ethics for CEO And Senior Financial Officers (incorporated by reference to exhibit 14.2 in our Registration Statement on Form S-1 filed on September 26, 2014)
(31)		Rule 13a-14 (d)/15d-14d) Certifications
31.1*		Section 302 Certification by the Principal Executive Officer
31.2*		Section 302 Certification by the Principal Financial Officer and Principal Accounting Officer
(32)		Section 1350 Certifications
32.1**		Section 906 Certification by the Principal Executive Officer
101*		Inline XBRL Document Set for the condensed financial statements and accompanying notes in Part I, Item 1, “Financial Statements” of this Quarterly Report on Form 10-Q.
104*		Inline XBRL for the cover page of this Quarterly Report on Form 10-Q, included in the Exhibit 101 Inline XBRL Document Set.

_________

*	Filed herewith.
**	Furnished herewith.

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

		PANAMERA HOLDINGS CORPORATION
		(Registrant)

Dated: March 17, 2022		/s/ T. Benjamin Jennings
		T. Benjamin Jennings
		President, Chief Executive Officer and Director
		(Principal Executive Officer)